美通社

2024-07-30 09:02

NCCN and Medlive Renew Collaboration to Enhance Cancer Care in China

United States-based National Comprehensive Cancer Network strengthens relationship with Chinese medical platform Medlive to broaden access to eminent oncology guidelines in China

PLYMOUTH MEETING, Pa., July 30, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer centers in the United States, is pleased to announce the renewal of its strategic collaboration with Medlive. This ongoing relationship will continue to facilitate the dissemination of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) across China via nccnchina.org.cn and Medlive's platforms for computer, smartphone, and tablet.

The NCCN Guidelines® provide evidence-based expert consensus-driven recommendations for cancer-related care. There are currently 88 different guidelines covering 97% of cancer incidence globally, plus recommendations for prevention, screening, and supportive care. NCCN Guidelines are accessible in China with enhanced download speeds and a streamlined registration process as a result of this joint effort.

"NCCN's mission is to improve and facilitate quality, effective, equitable, and accessible cancer care so that all patients can live better lives," said Crystal S. Denlinger, MD, Chief Executive Officer of NCCN. "We work tirelessly to provide the latest recommendations regarding appropriate cancer care to patients and health care professionals worldwide. This renewed collaboration with Medlive reinforces our commitment to global health by ensuring Chinese medical professionals and their patients have the critical resources needed to optimize cancer care."

NCCN's resources are globally recognized and utilized, with nearly half of the more than 1.9 million registered users accessing NCCN Guidelines living outside the United States as of June 2024. China is the second highest country for number of users, after the United States. Those users are responsible for more than 850,000 guideline downloads annually, many of them through Medlive.

"We are thrilled to continue working with NCCN to bring essential oncology resources to Chinese healthcare professionals through the Medlive platform," said Lixin Tian, President; Executive Director, Medlive. "This ongoing collaboration ensures that oncologists in China have rapid access to the widely respected NCCN Guidelines, facilitating high-quality, evidence-based patient care."

Jiangtao Xin, Vice President, Medlive, emphasized the importance of the reaffirmed affiliation: "Our work together serves as a bridge between oncology experts in China and the United States, allowing for mutual learning and better patient outcomes."

The two organizations will continue to cooperate to maintain the library of NCCN Guidelines on Medlive's platform, many of which are now available in Chinese as well as in English. For more information on NCCN's global initiatives to improve cancer care around the world, visit NCCN.org/global.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

 

source: National Comprehensive Cancer Network

【你點睇?】渣馬4名內地跑手被取消資格,4人同屬一個經理人,號碼布疑被調換,你認為主辦方應否酌情處理?► 立即投票

人氣文章
最近7天
1
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
2
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
3
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
4
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
5
高息定存 | 信銀國際12個月港元定存高達3.5厘
6
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
7
David Webb:因病情惡化,將有序結束個人財經網站
8
港股 | 蕭猷華:恒指短線回調,中線繼續看好
9
iPhone SE 4或於本周內上架官網
10
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
8
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
9
一本萬利 | 2025年的五個「勿」(有片)
10
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
11
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
14
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
15
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
16
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
17
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
18
習近平應約與特朗普通電話,特:冀盡快與習見面
19
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
20
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
21
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
22
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
23
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
24
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
25
特朗普就職 | 特朗普上台後行動列表
26
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
27
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
28
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
29
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
30
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老